PAT crashed 54% YoY; core business flattening masks subsidiary bleeding
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 5/10
Grade C
Guided for Packaging breakeven in FY27; revised to H1 FY28. Claimed 'no major changes' but PAT fell 54%. Vague on subsidiary profitability.
Cautiously Optimistic
next 1–2 quarters
Neutral
multi-year
Core Coding & Marking business is stagnating (3–4% growth, margin compression), while Packaging (V-Shapes) is a cash drain (₹65 Cr invested, breakeven pushed to FY28). PAT collapsed 54% YoY; management attributed this to externals (Iran, extrusion cyclicality) rather than structural margin erosion. Track & Trace remains unproven (₹20 Cr annual base, no growth). Risk: continued losses in subsidiaries and delayed return on capital.
₹115.6 Cr
Revenue · +3.8% YoY₹3.9 Cr
Reported PAT · −54.2% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Fundamentally nothing changed; core business steady
MISSPAT -54% YoY; revenue +3.8% vs prior 10% run-rate; OPM 13.2%, NPM 3.4%
Margins have not changed much; only FX impact
OVERSTATEDNPM 3.4% (very thin); PAT crashed despite COGS 2% improvement standalone
Track & Trace already profitable/breakeven, ~₹20 Cr FY26
UnverifiedManagement vague on Q1 actual; no P&L breakdown provided; ₹20 Cr unverified
V-Shapes: demand is there, execution issue only
METMachine reliability still below standard; moved from terrible to poor; no revenue traction claimed
No major market outlook changes; we can execute
PartialAdmitted external headwinds (Iran, extrusion cyclicality); delayed Assam capex 6+ months
Earnings quality
What changed since the last call
Packaging breakeven deferred
DowngradePreviously guided FY27 breakeven; now H1 FY28. Shiva admitted 'moving from terrible to poor' on V-Shapes; machine issues unresolved.
Core business growth slowed
DowngradeStandalone revenue +5% (₹100→105 Cr), consolidated +3.6%. Lagged prior run-rate; blamed extrusion/Iran but no quantified recovery timeline.
No new cost recovery plan
NeutralMentioned 'couple of price increases' but insufficient to offset sticky supplier cost increases; margins remain under pressure.
Track & Trace market clarity
UpgradeJuly 1, 2026 referenced but no enforcement; implementation timeline 2-phase, start FY28. Market expansion IF regulation passes.
The Q&A
Analysts pressed hard on PAT collapse, V-Shapes losses, and 'enough is enough' exit trigger. Shiva defended cautiously, acknowledged 'terrible to poor' progress, but refused to commit numbers or timelines. Deflected with macro (Iran, volatility) rather than owning execution gaps. Score: analysts held firm; management dodged profitability Q.
V-Shapes demand vs execution — Samarth Singh
AnsweredDemand real; execution issue (machine consistency, operator learning curve). Fixing 95/100 packet reliability; past sales didn't perform. Pivot to co-packaging and internal use.
Core business health — Saket Kapoor
PartialCore steady, 10–15% growth expected by FY27-end. Margin unchanged except FX. Suppliers exploiting stickiness; modest price increases taken. Careful on timing, not on maximizing short-term sales.
Subsidiary investment boundary — Saket Kapoor
DodgedOpportunity is big; not pulling plug now. Demand exists, we just need to execute. If no path forward, will take tough call, but issue is performance not opportunity.
Track & Trace timeline — Saloni Arya
PartialRunning pilots; each customer has own cycle (IQ, DQ, PQ); 1.5–2 year gestation. Already ₹20 Cr last FY at breakeven. Q3 will show progress.
Standalone Q1 slowness root cause — Saloni Arya
AnsweredIran uncertainty, polymer prices, extrusion cyclical. Q4 is typical strength; Q1 always slower. Expect catch-up in remaining 3 quarters.
Printer volume trend — Badri Narayana Ravi
Partial574 printers Q1. [Did not compare to prior quarters.] Consumables delayed due to extrusion slowdown; expect recovery.
Margin compression drivers — Vinit Thakur
PartialMargins unchanged except FX and slight consumables dip in Q1. Expect same trend for rest of year. Q2, Q3, Q4 on positive trend.
Track & Trace TAM and market share — Raj Vyas
AnsweredTAM ₹500–600 Cr. We captured ₹20 Cr last FY (~3% share). Two growth levers: unique propositions (market expansion + share) + government SKU expansion (300→1,000 brands, ₹600→₹1,500 Cr TAM).
Assam capex status — Diya Jain
AnsweredGovernment suspended new unit registrations under scheme. In limbo; waiting for government notice. Equipment ordered, ready, but no timeline.
V-Shapes breakeven timeline — Kewal Shah
AnsweredPackaging as whole likely H1 FY28, not H2 FY27. Will update Q2. UNNATI was planned for both C&M and Packaging but now in limbo.
Codeology/Markprint growth — Pranay Shah
PartialSaw some revenue growth across both; some machine orders delayed per customer request. Servicing from own Packaging facilities.
Macro headwinds and demand recovery — Raj Vyas
AnsweredJune back to normal. Volatility, not absolute price, is the issue. Raw material cost for co-packaging spiked; customer margins thin. Extrusion customer conservatism high.
QR code authentication gap — Chirag Barasara
AnsweredProblem NOT solved. QR codes still copyable; batch counterfeiting real. Our solution aims to address but is unproven. Problem 'still very much true.'
Exit criteria for loss-making units — Ashutosh Singh
DodgedQRiousCodes breakeven/profitable; no exit. International breakeven expected; no exit. Packaging: demand real, we're just not performing. Won't exit if path exists; will take tough call if no path.
Government Track & Trace mandate expansion — Parag Hinde
PartialStill in discussion; not enforced. 2-phase implementation over 2 years. Industry lobbying against. Won't happen by July 2026. Let's see final outcome.
Guidance
Core Coding & Marking FY27 +10–15%
MediumQ1 +3–5%; management expects catch-up in Q2–Q4 due to Q4 seasonality and extrusion recovery. Iran, polymer price volatility cited.
Packaging business stabilization FY27; revenue growth FY28
LowBreakeven pushed to H1 FY28 (deferred from FY27). Co-packaging pipeline expanding but machine issues unresolved.
Track & Trace TAM ₹600 Cr; government mandate could expand to ₹1,500 Cr
LowStill in discussion paper; no enforcement timeline. Phased 2-year rollout if approved. Company claims ₹20 Cr current base, only 3% share.
Standalone Coding & Marking 60% gross margin, 30% EBIT margin (per management aspiration)
LowCurrently near those levels but only if you exclude other business investments. Consolidated margin much lower due to subsidiary drag.
Consolidated OPM 13–14% (sustainable)
MediumQ1 OPM 13.2%. Unlikely to improve with V-Shapes still bleeding. Cost increases cited as 'sticky' and hard to pass through.
Assam UNNATI facility CapEx – indefinite hold
LowGovernment scheme suspended. Equipment ordered, registration ready. No restart date. Was planned for co-packaging + C&M; expected ₹100+ Cr capacity.
Risks the call surfaced
Subsidiary execution drag
HighV-Shapes bleeding; ₹65 Cr invested with marginal traction. Machine reliability still 95/100 (unacceptable for customers). Breakeven pushed to FY28 H1.
Core business deceleration
HighStandalone Coding & Marking +5% Q1 (vs typical 10%+ run-rate). Management attributes to extrusion/Iran but no structural fix communicated. Price increases only 'couple' despite sticky costs.
Track & Trace market timing
HighTrack & Trace TAM ₹600 Cr; CPL only ₹20 Cr (~3% share). Pharma pilots underway but 1.5–2 year gestation. Government QR mandate expansion still in discussion paper; no enforcement timeline; industry lobbying risk.
Capex slippage
MediumAssam UNNATI facility in limbo; government suspended new unit registrations. Co-packaging / laminates capacity expansion on hold. Expected revenue impact not quantified.
PAT deterioration unaddressed
MediumPAT -54% YoY (₹3.9 Cr) but management claimed 'no major changes' to PBT. Consolidated profit drivers not broken out. Implies subsidiary losses masked by claim of stable core.
Management
Score 5/10. Defensive and evasive. Acknowledged 'moving from terrible to poor' on V-Shapes but avoided quantified timelines. Vague on subsidiary profitability and consolidated drivers. Did not volunteer PAT -54% analysis. Mixed. Core business +3.8% vs prior 10%+ run-rate. Packaging breakeven pushed FY27→FY28 H1. Track & Trace in pilot stage, 3 years in. Digital printing absorbed but no material revenue yet.
1 · Q2 FY27 (Sep 2026)
Track & Trace pilot customer feedback; V-Shapes machine reliability update
2 · H1 FY28 (Jan 2027)
Packaging business target breakeven; CP Italy profitability inflection
3 · FY27-end (Mar 2027)
Government mandates QR-code Track & Trace for ₹1,500 Cr+ market (still in discussion; no enforcement timeline)
Risk: continued losses in subsidiaries and delayed return on capital.
PAT Crater Exposes the Hollow Core
Management claimed 'fundamentally nothing changed,' but net profit collapsed 54% YoY while revenue inched up 3.8%. The Q&A reveals what they're not saying: subsidiaries are bleeding, capex is blocked, and the core business is decelerating.
₹115.6 Cr
+3.8% YoY
₹3.9 Cr
-54.2% YoY; NPM 3.4%
+3–5%
vs. prior 10%+ run-rate
₹572
-28.5% from ATH; RSI 27.9
Control Print's Q1 result opened with a +3% pop on day 1, but the move faded to -0.7% by day 5. That tape action is the market's verdict on the quarter: initial relief that the number wasn't worse, followed by a slow recognition that the story underneath is deteriorating, not stable.
The headline vs. the consolidated truth
Management's opening gambit: 'Fundamentally nothing changed; core business is steady.' Yet net profit fell 54% YoY on just 3.8% revenue growth. That gap is not reconcilable without consolidated P&L transparency that management never provided. The call transcript reveals why: subsidiaries are bleeding. CP Italy (V-Shapes packaging) is bleeding. Codeology and Markprint show 'some revenue growth' but no profit numbers. The consolidated profit drivers are hidden.
Fundamentally, the difference in profit before on a standalone basis is partly down to FX gains or something...there's still a slight gap after that.
This non-answer is the heart of the credibility issue. Management deflected to FX without explaining how a 200-basis-point improvement in standalone COGS (44% → 42%) combined with only a 'couple' of price increases produces a 54% collapse in consolidated net profit. The answer is: the subsidiaries are losing more, and the core business is decelerating.
Fundamentally nothing changed; core business steady
PAT -54% YoY; revenue +3.8% vs prior 10% run-rate; NPM 3.4%, OPM 13.2%. Subsidiary losses mask the decline.
Contradicted
Margins have not changed much; only FX impact
NPM collapsed to 3.4% (very thin); standalone COGS improved 200 bps but consolidated profit crashed. FX blame doesn't reconcile the math.
Overstated
V-Shapes demand is real, execution issue only
Management: 'Moving from terrible to poor' on machine reliability. Demand may exist but ROI on ₹65 Cr invested is nowhere in sight; breakeven pushed to H1 FY28.
Supported, but expensive
Track & Trace already at ₹20 Cr revenue, breakeven
No Q1 actual disclosed; said 'similar' to prior year without numbers. Pilots running 1.5–2 years; government mandate still in discussion, no enforcement timeline.
Unverified
No major market outlook changes; we can execute
Admitted Iran uncertainty, polymer price volatility, extrusion cyclicality. Assam capex (UNNATI) delayed indefinitely due to government scheme suspension.
Partial
What changed on this call vs. prior guidance
Packaging (V-Shapes) breakeven: FY27 → H1 FY28 (deferred 6–9 months)
Core Coding & Marking growth: 10%+ prior run-rate → 3–5% Q1 actual; guidance 10–15% by FY27-end (unsupported by current trajectory)
Assam UNNATI capex: indefinite hold; government scheme suspended; no restart timeline
Track & Trace government TAM expansion: ₹600 Cr → ₹1,500 Cr potential if 300→1,000 SKU mandate passes; still in discussion, no enforcement yet
No new cost recovery mechanism; 'couple' of price increases insufficient vs. sticky supplier costs
The bull-bear ledger
Market leader in domestic Coding & Marking (cement, plywood, sugar, dairy customers)
Core business consumables revenue (recurring, high-margin) on 574 printer installed base
Standalone COGS improved 200 bps (44% → 42%) despite supplier cost inflation
PAT -54% YoY unexplained; consolidated P&L hidden; management credibility weakened
Core growth stagnating (3–5% Q1 vs. 10%+ prior run-rate); guidance (10–15% by FY27-end) appears unrealistic
V-Shapes: ₹65 Cr sunk, breakeven pushed to H1 FY28, machine reliability still below standard (95/100 packets)
Track & Trace: ₹20 Cr revenue unverified for Q1, 3% market share, pilots 1.5–2 year gestation; government mandate still pending
Assam capex (₹100+ Cr revenue potential) indefinitely blocked; strategic capacity expansion halted
Stock oversold (RSI 27.9, down 28.5% from ATH), but price action faded by day 5 (initial +3% → -0.7%); market skepticism holds
How the street is positioned
Price action: The stock opened with a day-1 pop of +3.02% on announcement (day-3 drifted to +2.88%). By day 5, the pop had completely faded to -0.7%. This is a textbook rejection of a quarterly result by the market: initial relief that the company didn't miss worse, followed by a slow realization that the underlying trend is deteriorating. The volume is decreasing, and the stock remains below all major simple moving averages (SMA20 ₹627.39, SMA50 ₹625.32, SMA200 ₹663.28).
Valuation and technicals: The stock sits at ₹572, down 28.5% from its all-time high of ₹800, and currently trades in the 52-week range of ₹518.95–₹800. The RSI of 27.9 signals oversold territory — technically a contrarian buy signal for a healthy business. But the technicals don't resolve the fundamental problem: the business is decelerating, subsidiaries are bleeding, and management's credibility is damaged. Oversold technicals are a trap if the earnings trajectory doesn't reverse.
Institutional flows: FII ownership has declined from 3.47% in Q4 FY25 to 3.15% in Q4 FY26 (a -0.12pp trimming QoQ). DII ownership is minimal and also trimming. Promoter ownership remains steady at 52.98%. The institution-trimming combined with the market's skeptical price action signals low confidence in the next 2–3 quarters of execution.
The debate
Risks, ranked by severity to a holder
Subsidiary execution drag (V-Shapes, Codeology, Markprint, CP MEA)
HighCP Italy machine reliability still 95/100 packets (unacceptable for customers). ₹65 Cr sunk; breakeven pushed to H1 FY28. Codeology/Markprint growth unquantified. No exit criteria defined. If subsidiaries don't turn profitable by FY28, capital allocation questions will mount.
Core business deceleration (Coding & Marking +3–5% Q1 vs. 10%+ run-rate)
HighStandalone revenue only +5% Q1. Management blamed Iran and extrusion cyclicality but expects 10–15% by FY27-end (unsupported by current trajectory). If Q2–Q4 doesn't show acceleration, guidance miss is certain. Margin recovery also at risk if price increases can't keep pace with sticky supplier costs.
Track & Trace TAM and market timing (1.5–2 year pilot gestation; government mandate unconfirmed)
HighCurrent revenue ₹20 Cr unverified for Q1 (only 3% of ₹600 Cr TAM). Pilots are 3 years old with no revenue inflection. Government QR mandate expansion (₹600→₹1,500 Cr) is still in discussion, no enforcement timeline. If pilots don't convert to revenue by H1 FY28 or the government mandate stalls, this big bet evaporates.
Capex slippage (Assam UNNATI facility indefinitely blocked)
MediumGovernment scheme suspended; no restart date. Equipment is ready but sitting idle. Expected ₹100+ Cr revenue-capable capacity is lost. Strategic co-packaging + laminates expansion on hold. If UNNATI doesn't restart within 12 months, CPL's supply-chain scalability is constrained.
PAT deterioration unaddressed (consolidated P&L opacity; management credibility)
MediumPAT -54% YoY is a red flag. Management claimed 'no major changes' but provided no reconciliation. Subsidiary P&L not disclosed. If Q2 shows another PAT decline or sideways result, analyst coverage will turn more negative and the stock will face selling pressure.
What to watch next
1 · Q2 FY27: Core Coding & Marking growth trajectory
Standalone revenue should show acceleration to 8%+ to justify the 10–15% full-year guidance. Consumables recovery (extrusion demand normalization) is the key driver. If Q2 is still flat (0–3% growth), the FY27 guidance is off the table.
2 · Q2 FY27: Track & Trace pilot feedback and revenue traction
Management promised 'similar' revenue to prior year (₹20 Cr+) and said Q3 would show progress. By Q2, at least one pharma pilot should show positive DQ/PQ (validation). Any pilot delays or contract cancellations would undermine the Track & Trace thesis.
3 · H1 FY27: V-Shapes machine reliability and order flow
Management admitted 95/100 packet consistency (still unacceptable). If machine issues persist or the 'couple' of co-packaging customer contracts show margin compression (raw material spikes), the path to H1 FY28 breakeven will look unrealistic.
4 · Government Track & Trace mandate announcement (timeline TBD)
The ₹1,500 Cr TAM expansion depends on a government notice. If the mandate is delayed beyond FY28 or faces industry lobbying rollback, the Track & Trace TAM remains ₹600 Cr and growth will be limited to organic share gains.
5 · Government UNNATI scheme restart (timeline TBD)
Assam facility capex is blocked. A restart notice would unlock ₹100+ Cr capacity and derisk the co-packaging expansion. No restart within 12 months signals government deprioritization of the scheme.
Control Print's Q1 is a quarter where the headline (revenue +3.8%) masks the reality: net profit crashed 54%, subsidiaries are bleeding, core growth is decelerating, and management's credibility is damaged by defensive Q&A and missed guidance. The stock's 28% drawdown from ATH is warranted, not a buying opportunity.
The honest read is a Hold, not a Buy. The core business is not broken—it has pricing power and a strong installed base—but it is stagnating under margin pressure. The big bets (V-Shapes and Track & Trace) face execution and regulatory headwinds. Until Q2 shows core growth re-acceleration to 8%+ and V-Shapes/Track & Trace progress, the stock should trade sideways to lower. The number to track from here is standalone Coding & Marking growth: if it's still 0–5% in Q2, the full-year guidance is off the table, and the stock will re-rate down further.
Control Print Q1: consolidated PAT slumps 54% YoY to ₹3.9 Cr as overseas losses bite
PAT -54.2% YoY · revenue +3.8% · margins compressing
₹115.56 Cr
+3.8% YoY
₹3.92 Cr
-54.2% YoY
3.39%
-4.3pp YoY
₹2.45
Control Print's Q1 FY27 was a weak print on profitability despite steady topline. Consolidated revenue rose just 3.8% YoY to ₹115.56 Cr (down 17.4% sequentially off a seasonally strong Q4), but consolidated PAT collapsed 54.2% YoY to ₹3.92 Cr from ₹8.56 Cr, and 65% QoQ. Net margin compressed to 3.4% from 7.7% a year ago and 8.0% last quarter. The decline is actually understated by the reported number: the year-ago quarter carried a ₹3.99 Cr exceptional loss, so on a clean, one-off-adjusted basis underlying consolidated PAT is down roughly 66% YoY — this is a genuine operating deterioration, not an optics artefact.
Q1 FY-2027 vs prior quarters
The drag is overseas. The auditor's report flags that the foreign wholly-owned and step-down subsidiaries (Control Print BV, CP Italy, Mark Print, Codeology, MEA) together booked a ₹8.24 Cr net loss for the quarter. That is why the two bases diverge sharply: standalone PAT of ₹12.39 Cr (EPS ₹7.75) held up far better than consolidated ₹3.92 Cr (EPS ₹2.45), though even standalone profit fell ~42% YoY on a ~31% drop in pre-exceptional PBT. Readers will see both numbers — the India business remains solidly profitable; it is the international packaging/V-Shapes footprint that is bleeding.
The stock went into the print at ₹624.75, down 1.8% over the past month of trading.
Management reiterated a commitment to optimizing costs and enhancing operational efficiency. The coding and marking business is expected to maintain steady growth, supported by an increasing install base and new solutions. The Track and Trace segment is anticipated to become a revenue contributor, potentially reaching
— This quarter: missed
Against management's own last-call guidance the quarter reads as a miss on the profitability timeline: the Q4 concall promised CP Italy restructuring toward breakeven and Track & Trace turning a contributor in the current fiscal, yet foreign operations deepened losses this quarter. The core Coding & Marking franchise (single reportable segment) delivered only low-single-digit revenue growth, so there is no offsetting acceleration on the India side. No brokerage consensus exists for this small-cap ahead of the result. Concurrent corporate action: the board's ₹6 final dividend (record date July 10) relates to FY26, and a related-party IP assignment from CP Italy for ₹31.20 Cr was booked as intangible-under-development during the quarter. Management hosts an earnings call on July 24 where the overseas turnaround timeline will be the key question.
W1
Foreign subsidiary losses (₹8.24 Cr this quarter) — whether CP Italy restructuring narrows them toward the promised breakeven
W2
Track & Trace turning a revenue contributor / breakeven in FY27 as management guided on the Q4 call
W3
Standalone pre-exceptional PBT recovery — down 31% YoY (₹18.22 Cr vs ₹26.56 Cr); watch if core margin stabilises
Source in ₹ Lakhs; converted to Cr. otherIncome combines the statement's 'Other income' + separate 'Foreign exchange fluctuation' line so totalIncome reconciles (std 202.28+19.78; cons 7.10+9.69 Lakhs). No exceptional item this quarter; year-ago Q1FY26 carried a ₹3.99 Cr exceptional loss (both bases) — adjusting for it steepens the YoY PAT fall. Consolidated PAT is 'profit for period from continuing ops' (line 7); NCI separate. Auditor note: foreign subsidiaries booked ₹8.24 Cr net loss for the quarter, the main gap between standalone and consolidated PAT.